Table 2.
Organism* (FQR N/Total N Tested) | AK | A/S | CPE | CTF | CFX | CAZ | CAX | ETP | IMP | P/T |
---|---|---|---|---|---|---|---|---|---|---|
A. baumannii (30/57) | 37 | 23 | 7 | 3 | na | 7 | 7 | na | 43 | 10 |
C. freundii (5/50) | 100 | 20 | 80 | 40 | 0 | 40 | 40 | 80 | 80 | 60 |
E. aerogenes (2/58) | 100 | 0 | 50 | 0 | 50 | 0 | 0 | 50 | 100 | 50 |
E. cloacae (23/140) | 83 | 0 | 57 | 4 | 4 | 17 | 4 | 35 | 100 | 26 |
E. coli (763/2163) | 93 | 14 | 65 | 55 | 76 | 56 | 56 | 96 | 99 | 86 |
ESBL+ (300/367) | 88 | 7 | 12 | 0 | 74 | 0 | 0 | 95 | 100 | 81 |
ESBL− (463/1796) | 97 | 19 | 99 | 91 | 77 | 92 | 92 | 97 | 99 | 89 |
K. oxytoca (8/86) | 87 | 0 | 38 | 25 | 87 | 25 | 25 | 87 | 100 | 38 |
ESBL+ (6/13) | 83 | 0 | 17 | 0 | 83 | 0 | 0 | 83 | 100 | 17 |
ESBL− (2/73) | 100 | 0 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
K. pneumoniae (96/582) | 74 | 4 | 26 | 18 | 48 | 21 | 17 | 57 | 79 | 34 |
ESBL+ (65/135) | 78 | 0 | 8 | 0 | 51 | 0 | 0 | 55 | 88 | 25 |
ESBL− (31/447) | 65 | 13 | 65 | 55 | 42 | 65 | 52 | 61 | 61 | 52 |
M. morganii (8/49) | 100 | 0 | 38 | 38 | 50 | 50 | 38 | 100 | 50 | 100 |
P. mirabilis (38/209) | 84 | 37 | 81 | 55 | 73 | 60 | 55 | 100 | 27 | 90 |
ESBL+ (10/18) | 60 | 30 | 40 | 0 | 80 | 0 | 0 | 100 | 20 | 100 |
ESBL− (28/191) | 93 | 39 | 96 | 75 | 71 | 82 | 75 | 100 | 29 | 86 |
P. aeruginosa (124/295) | 62 | na | 31 | 7 | na | 49 | 8 | na | 54 | 73 |
S. marcescens (3/47) | 67 | 0 | 67 | 0 | 0 | 67 | 33 | 67 | 67 | 33 |
All FQR Isolates Combined (1100/3781) | 86 | 13 | 56 | 44 | 61 | 57 | 44 | 78 | 88 | 76 |
C. koseri (n=45) not included as all were fluoroquinolone-susceptible.
AK, Amikacin; A/S, Ampicillin-Sulbactam; CPE, Cefepime; CTF, Cefotaxime; CFX, Cefoxitin; CAZ, Ceftazidime; CAX, Ceftriaxone; ETP, Ertapenem; IMP, Imipenem; P/T, Piperacillin-Tazobactam. na, CLSI breakpoints not available for this species/drug combination (na’s were calculated as resistant for purposes of Grand Total percentages).